Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal

BMC Research Notes

Chandrika Devi Shrestha¹  Anil Chander¹ 

[1] Department of Microbiology, Kathmandu Medical College Teaching Hospital Sinamangal / Duwakot, Kathmandu, Nepal

关键词: Urinary isolates;    Prevalence;    Mid stream urine (MSU);    Klebsiella pneumoniae;    Escherichia coli;    Extended spectrum beta lactamase (ESBL);    Antimicrobial resistance;   

Others  :  1140683
DOI  :  10.1186/1756-0500-6-487

 received in 2013-07-23, accepted in 2013-11-23,  发布年份 2013

【 摘 要 】

Background

Escherichia coli and Klebsiella pneumoniae are the major bacterial pathogens being isolated and reported from mid stream urine (MSU) specimens, globally. These uropathogens are mostly implicated as the major extended spectrum beta-lactamase (ESBL) producers, severely limiting the therapeutic management in cases of urinary tract infections. Limited studies had been reported from Nepal investigating the ESBL producers among uropathogens. This study was designed to assess the prevalence of ESBL producing E.coli and K. pneumoniae in urinary isolates at a centrally located major tertiary care hospital in Kathmandu valley, Nepal.

Methods

Between September 2011 and May 2012, during the nine months period, 6308 MSU specimens were collected aseptically from the same number of clinically suspected patients of urinary tract infections. The samples were cultured on MacConkey agar and blood agar. The isolates with significant bacteriuria (10⁵ CFU / ml) were identified based on standard laboratory procedures. Antimicrobial susceptibility tests were carried out using various antimicrobial discs alongwith ceftriaxone on E.coli and K. pneumoniae isolates by Kirby Bauer disc diffusion method as per the recommendations of CLSI. On initial screening with ceftriaxone (30 μg) disc showing resistance was then confirmed for ESBL production by phenotypic confirmatory disc diffusion test (PCDDT) using ceftazidime (30 ug) and ceftazidime + clavulanic acid (30 μg + 10ug) disc as per guidelines of CLSI (2011).

Results

Out of a total of 6308 MSU specimens investigated for significant bacteriuria, E.coli isolates were 444 (7.04%) and K.pneuminiae were 145 (2.3%) making a total of 589 (9.34%). Initial screening with ceftriaxone disc revealed 155 isolates of E.coli and 70 isolates of K.pneumoniae to be resistant. Further testing by PCDDT method showed 60/444 (=13.51%) of E. coli and 24/145 (=16.55%) of K. pneumoniae isolates to be confirmed ESBL producers. These ESBL – producer uropathogens showed high degree of resistance to ceftriaxone (100.0%), amoxycillin, fluoroquinolones and co-trimoxazole.

Conclusion

An emerging and moderately high prevalence of ESBL-producing E. coli and K. pneumoniae was observed and confirmed in the urinary isolates investigated. It is essential to have a regular and routine monitoring of ESBL producing clinical isolates in laboratory practice.

【 授权许可】

   
2013 Chander and Shrestha; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ullah F, Malik SA, Ahmed J: Antibiotic susceptibility pattern and ESBL prevalence in nosocomial Escherichia coli from urinary tract infections in Pakistan. Afr J Biotechnol 2009, 8(16):3921-3926.
• [2]Cox CE: Nosocomial urinary tract infections. Urol 1988, 32(3):210-215.
• [3]Gonzalez CM, Schaeffer AJ: Treatment of urinary tract infection: what’s old, what’s new, and what works. World J Urol 1999, 17(6):372-382.
• [4]Coque TM, Baquero F, Canton R: Increasing prevalence of ESBL producing enterobacteriaceae in Europe. Eurosurveillance 2008, 13(47):1-11.
• [5]Paterson DL, Bonomo RA: Extended spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005, 18(4):657-686.
• [6]Bradford PA: Extended spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001, 14(4):933-951.
• [7]Jacoby GA, Munoz-Price LS: The new beta-lactamases. New Engl J Med 2005, 352(4):380-391.
• [8]Rupp ME, Fey PD: Extended spectrum β-lactamase (ESBL)- producing enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003, 63(4):353-365.
• [9]Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ: Nosocomial outbeak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993, 119:353-358.
• [10]Naumovsky L, Quinn JP, Miyashiro D, Patel M, Bush K, Singer SB, et al.: Outbreak of ceftazidime resistance due to a novel extended spectrum β-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992, 36:1991-1996.
• [11]Schiappa DA, Hayden MK, Matushek MG, Hashemi FN, Sullivan J, Smith KY, et al.: Ceftazidime resistant Klebsiella pneumoniae and Escherichia coli blood stream infection: a case control and molecular epidemiologic investigation. J Infect Dis 1996, 174:529-536.
• [12]Paterson DL, Mulazimoglu L, Casellas JM, Ko W-C, Goossens H, Gottberg AV, et al.: Epidemiology of ciprofloxacin resistance and its relationship to extended spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000, 30:473-478.
• [13]Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G: The Italian ESBL Study Group. Occurrence of extended spectrum β-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002, 46:196-202.
• [14]Jacoby GA, Sutton L: Properties of plasmids responsible for production of extended spectrum β-lactamases. Antimicrob Agents Chemother 1991, 35:164-169.
• [15]Poirel M, Le Thomas I, Naas T, Karim A, Nordmann P: Biochemical sequence analyses of GES-1, a novel class A extended spectrum β-lactamase, and the Class I integrin In52 from Klebsiella pneumoniae. Antimicrob Agents Chemother 2000, 44:622-632.
• [16]Bonnet R: Growing group of extended spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004, 48(1):1-14.
• [17]Falagas ME, Karageorgopoulos: Extended spectrum β-lactamase-producing organisms. J Hosp Infect 2009, 73(4):345-354.
• [18]Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ: Antimicrobial susceptibility among organisms from the Asia/ Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007, 60(5):1018-1029.
• [19]Villegas MV, Kattan JN, Quinteros MG, Casselas JM: Prevalence of extended-spectrum β-lactamases in South America. Clin Microbiol Infect 2008, 14(Suppl. 1):154-158.
• [20]Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC: SENTRY antimicrobial surveillance program report; Latin America and Brazilian results for 1997 through 2001. Braz J Infect Dis 2004, 8(1):25-79.
• [21]Poudyal S, Bhatta DR, Shakya G, Upadhyaya B, Dumre SP, Buda G, et al.: Extended spectrum β-lactamase producing multidrug resistant clinical bacterial isolates at National Public Health Laboratory, Nepal. Nepal Med Coll J 2011, 13(1):34-38.
• [22]Shrestha S, Amatya R, Dutta R: Prevalence of extended spectrum beta lactamase (ESBL) production in gram negative isolates from pyogenic infection in tertiary care hospital of Eastern Nepal. Nepal Med Coll J 2011, 13(3):186-189.
• [23]Baral P, Neupane S, Marasini BP, Ghimire KR, Lekhak B, Shrestha B: High prevalence of multidrug resistance in bacterial uropathogens from Kathmandu, Nepal. BMC Res Notes 2012, 5:38. BioMed Central Full Text
• [24]Collee JG, Miles RS, Watt B: Tests for identification of bacteria. In Mackie and McCartney Practical Medical Microbiology. 14th edition. Edited by Collee JG, Fraser AG, Marmion BP, Simmons A. New York: Churchill Livingstone; 1996:131-149.
• [25]Clinical Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; Twenty First informational supplement (M 100-S21). Wayne PA: Clinical and Laboratory Standards Institute; 2011.
• [26]Habte TM, Dube S, Ismail N, Hoosen AA: Hospital and community isolates of uropathogens at a tertiary hospital in South Africa. S Afr Med J 2009, 99:584-587.
• [27]Matute AJ, Hak E, Schurink CAM, McArthur A, Alonso E, Pantagua M, et al.: Resistance of uropathogens in symptomatic urinary tract infections in Leon, Nicaragua. Int J Antimicrob Agents 2004, 23:506-509.
• [28]Tambekar DH, Dhanorkar DV, Gulhane DR, Khanadelwal VK, Dudhane MN: Antibacterial susceptibility of some urinary tract pathogens to commonly used antibiotics. Afr J Biotechnol 2006, 5:1562-1565.
• [29]Durmaz R, Durmaz B, Koroglu M, Tekerekoglu MS: Detection and typing of extended- spectrum β-lactamases in clinical isolates of the family Enterobacteriaceae in a medical center in Turkey. Microb Drug Resist 2001, 7:171-175.
• [30]Babypadmini S, Appalaraju B: Extended spectrum lactamase in urinary isolates of E.coli and Klebsiella pneumoniae - prevalence and susceptibility patterns in a tertiary care hospital. Indian J Med Microbiol 2004, 22:172-174.
• [31]Aminzadeh Z, Sadat KM, Sha’bani M: Bacteriuria by extended spectrum beta-lactamase producing E.coli and Klebsiella pneumoniae isolates in a government hospital in south of Tehran, Iran. Iran J Kidney Dis 2008, 2:197-200.
• [32]Ahmed SM, Jakribettu RP, Koyakutty S, Arya B, Shakir VPA: Urinary tract infections – an overview on the prevalence and the anti-biogram of gram negative uropathogens in a tertiary care center in North Kerala, India. J Clin Diagn Res 2012, 6:1192-1195.
• [33]Oladeinde BH, Omoregie R, Olley M, Anunibe JE: Urinary tract infections in a rural community of Nigeria. North Amer J Med Sci 2011, 3:75-77.
• [34]Dalela G, Gupta S, Jain DK, Mehta P: Antibiotic resistance patterns in uropathogens at a tertiary care hospital at Jhalawar with special reference to ESBL, AmpC b-lactamase and MRSA production. J Clin Diagn Res 2012, 6(4):645-651.
• [35]Randrianirina F, Soares J-L, Carod J-F, Ratsima E, Thonnier V, Combe P, et al.: Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar. J Antimicrob Chemother 2007, 59:309-312.
• [36]Behrooozi A, Rahbar M, Yousefi JV: Frequency of extended spectrum beta-lactamase (ESBLs) producing Escherichia coli and Klebsiella pneumoniae isolated from urine in an Iranian 1000-bed tertiary care hospital. Afr J Microbiol Res 2010, 4(9):881-884.
• [37]Pathak A, Marothi Y, Kekre V, Mahadik K, Macaden R, Lundborg CS: High prevalence of extended spectrum β-lactamase producing pathogens: results of a surveillance study in two hospitals in Ujjain, India. Infect Drug Resist 2012, 5:65-73.
• [38]Alipourfard I, Nili NY: Antibiogram of extended spectrum beta-lactamase (ESBLs) producing Escherichia coli and Klebsiella pneumoniae isolated from hospital samples. Bangladesh J Med Microbiol 2010, 4(1):32-36.
• [39]van der Donk CFM, van de Bovenkamp JHB, De Brauwer EIGB, De Mol P, Feldhoff K-H, Kalka-Moll WM, et al.: Antimicrobial resistance and spread of multi drug resistant Escherichia coli isolates collected from nine urology services in the Euregion Meuse-Rhine. PLoS One 2012, 7(10):e47707.
• [40]Abdullah FE, Mushtaq A, Irshad M, Rauf H, Afzal N, Rasheed A: Current efficacy of antibiotics against Klebsiella isolates from urine samples – a multi-centric experience in Karachi. Pak J Pharm Sci 2013, 26(1):11-15.
• [41]Gonzalez LS, Spencer JP: Aminoglycosides: a practical review. Am Fam Physician 1998, 58(8):1811-1820.